AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...
The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.
Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 14th of February ...
AbbVie has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of AbbVie (NYSE:ABBV) with a Outperform ...
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
Zacks.com on MSN2d
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...
AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...
At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback